etoposide has been researched along with navitoclax in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akao, Y; Horiike, S; Kobayashi, S; Kobayashi, T; Kuroda, J; Matsumoto, Y; Nagoshi, H; Nishida, K; Sasaki, N; Shimura, Y; Taki, T; Taniwaki, M; Tsutsumi, Y; Yamamoto, M | 1 |
| Anderson, DJ; Belmont, LD; Bouillet, P; Campbell, KJ; Cory, S; Fairlie, WD; Glaser, SP; Huang, DC; Khaw, SL; Lee, EF; Ludlam, MJ; Mérino, D; Phipson, B; Robati, M; Roberts, AW; Vandenberg, CJ; Wong, C; Yue, P | 1 |
| Cha, HJ; Go, YH; Hong, SK; Kwon, OS; Kwon, SJ; Oh, E | 1 |
| Alotaibi, MR; Carpenter, VJ; Faber, AC; Gewirtz, DA; Harada, H; Leverson, JD; Murray, G; Reed, J; Saleh, T; Souers, AJ; Tyutyunyk-Massey, L | 1 |
| Beijersbergen, RL; Bernards, R; De Conti, G; Groot, K; Jansen, R; Jin, H; Jochems, F; Leite de Oliveira, R; Pogacar, Z; Schepers, A; Thijssen, B; Wang, C; Wang, L; Wessels, LFA | 1 |
| Bode, P; Manzella, G; Moonamale, DC; Römmele, M; Schäfer, BW; Wachtel, M | 1 |
6 other study(ies) available for etoposide and navitoclax
| Article | Year |
|---|---|
Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Topics: Aniline Compounds; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; Spectral Karyotyping; Sulfonamides; Thiazoles; Translocation, Genetic | 2011 |
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Topics: Aniline Compounds; Animals; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-X Protein; Biphenyl Compounds; Cell Death; Cytoprotection; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Lymphoma; Membrane Proteins; Mice; Molecular Targeted Therapy; Mutant Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2012 |
BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biphenyl Compounds; Cell Proliferation; Cell Survival; Chemoradiotherapy; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Molecular Mimicry; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; RNA Interference; Signal Transduction; Sulfonamides; Transfection; Up-Regulation | 2017 |
Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X
Topics: Aniline Compounds; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carcinogenesis; Cell Death; Cell Line, Tumor; Cellular Senescence; Doxorubicin; Etoposide; HEK293 Cells; Humans; Male; Models, Biological; Protein Binding; Radiation; Sulfonamides; Topoisomerase Inhibitors; Tumor Burden | 2020 |
The Cancer SENESCopedia: A delineation of cancer cell senescence.
Topics: Aniline Compounds; Azepines; Cell Line, Tumor; Cellular Senescence; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Pyrimidines; Reproducibility of Results; Senescence-Associated Secretory Phenotype; Senotherapeutics; Sulfonamides | 2021 |
A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; bcl-X Protein; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; Rhabdomyosarcoma; Sulfonamides; Xenograft Model Antitumor Assays | 2021 |